United States · 
Who invested in Syntimmune?
Syntimmune's investors include Apple Tree Partners.
United States · Series B startup
Who invested in Syntimmune
Funding summaryUpdated 26 Oct 2026
$50Mraised across 1 round since 2017, from 1 source
- Latest round
- Series B, $50MJun 2017
- Investors
- 1
The rounds
- Jun 2017
Founders and team
From Syntimmune's own website and the SEC filings it signed: 11 on the team.
- Marc DunoyerChief Executive Officer
- Sean ChristieChief Financial and Administration Officer
- Erica DeaconVP, Head of Information Technology
- Gianluca PirozziSVP, Head of Development, Regulatory and Safety
- Nicola HeffronSVP, Head of Global Marketing & Market Access
- Scott WeintraubSVP, Head of Development, Regulatory and Safety
- Seng ChengSVP, Head of Research and Product Development
- Shane DoyleSVP, Head of Operations
- Toby FreymanVP, Head of Business Development
- David De GraafExecutive Officer, Directori
- Laurence BlumbergExecutive Officer, Directori
On the board, as filediAaron KantoffBurt AdelmanRichard BlumbergSam HallSeth Harrison
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Syntimmune
How much has Syntimmune raised?
Syntimmune has raised $50M across 1 round since 2017.
When did Syntimmune last raise?
Syntimmune's most recent round was a Series B of $50M in Jun 2017.
What was Syntimmune's biggest round?
Its most recent round, $50M in Jun 2017, is also its largest on record.
Who backed Syntimmune first?
Syntimmune's first round on record, in Jun 2017, was backed by Apple Tree Partners.
What stage is Syntimmune at?
Syntimmune's latest named round is a Series B, in Jun 2017.
Where is Syntimmune based?
Syntimmune is based in the United States.
Companies like Syntimmune
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.